These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 26721703)

  • 1. Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.
    Backman JT; Filppula AM; Niemi M; Neuvonen PJ
    Pharmacol Rev; 2016 Jan; 68(1):168-241. PubMed ID: 26721703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucuronides as Potential Anionic Substrates of Human Cytochrome P450 2C8 (CYP2C8).
    Ma Y; Fu Y; Khojasteh SC; Dalvie D; Zhang D
    J Med Chem; 2017 Nov; 60(21):8691-8705. PubMed ID: 28653847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative Rationalization of Gemfibrozil Drug Interactions: Consideration of Transporters-Enzyme Interplay and the Role of Circulating Metabolite Gemfibrozil 1-O-β-Glucuronide.
    Varma MV; Lin J; Bi YA; Kimoto E; Rodrigues AD
    Drug Metab Dispos; 2015 Jul; 43(7):1108-18. PubMed ID: 25941268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters.
    Tornio A; Neuvonen PJ; Niemi M; Backman JT
    Expert Opin Drug Metab Toxicol; 2017 Jan; 13(1):83-95. PubMed ID: 27548563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interplay of UDP-Glucuronosyltransferase and CYP2C8 for CYP2C8 Mediated Drug Oxidation and Its Impact on Drug-Drug Interaction Produced by Standardized CYP2C8 Inhibitors, Clopidogrel and Gemfibrozil.
    Iga K; Kiriyama A
    Clin Pharmacokinet; 2024 Jan; 63(1):43-56. PubMed ID: 37921907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions.
    Ogilvie BW; Zhang D; Li W; Rodrigues AD; Gipson AE; Holsapple J; Toren P; Parkinson A
    Drug Metab Dispos; 2006 Jan; 34(1):191-7. PubMed ID: 16299161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of CYP2C8 by Acyl Glucuronides of Gemfibrozil and Clopidogrel: Pharmacological Significance, Progress and Challenges.
    Shah MB
    Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Underlying mechanism of drug-drug interaction between pioglitazone and gemfibrozil: Gemfibrozil acyl-glucuronide is a mechanism-based inhibitor of CYP2C8.
    Takagi M; Sakamoto M; Itoh T; Fujiwara R
    Drug Metab Pharmacokinet; 2015 Aug; 30(4):288-94. PubMed ID: 26195223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.
    Marzolini C; Rajoli R; Battegay M; Elzi L; Back D; Siccardi M
    Clin Pharmacokinet; 2017 Apr; 56(4):409-420. PubMed ID: 27599706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions.
    Tornio A; Filppula AM; Kailari O; Neuvonen M; Nyrönen TH; Tapaninen T; Neuvonen PJ; Niemi M; Backman JT
    Clin Pharmacol Ther; 2014 Oct; 96(4):498-507. PubMed ID: 24971633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate.
    VandenBrink BM; Foti RS; Rock DA; Wienkers LC; Wahlstrom JL
    Drug Metab Dispos; 2011 Sep; 39(9):1546-54. PubMed ID: 21697463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.
    Backman JT; Honkalammi J; Neuvonen M; Kurkinen KJ; Tornio A; Niemi M; Neuvonen PJ
    Drug Metab Dispos; 2009 Dec; 37(12):2359-66. PubMed ID: 19773535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Safety and Clinically Relevant Drug-Drug Interactions with Tucatinib in Healthy Volunteers.
    Topletz-Erickson A; Lee A; Rustia EL; Sun H; Mayor JG; Abdulrasool LI; Walker L; Endres CJ
    Clin Pharmacokinet; 2022 Oct; 61(10):1417-1426. PubMed ID: 35931943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-Dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans.
    Itkonen MK; Tornio A; Neuvonen M; Neuvonen PJ; Niemi M; Backman JT
    Drug Metab Dispos; 2019 Apr; 47(4):377-385. PubMed ID: 30630815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of inhibition of CYP2C8 by saroglitazar magnesium: In vivo assessment using montelukast, rosiglitazone, pioglitazone, repaglinide and paclitaxel as victim drugs in Wistar rats.
    Giri P; Delvadia P; Ladani MK; Prajapati N; Gupta L; Patel N; Joshi V; Giri S; Jain MR; Srinivas NR; Patel PR
    Eur J Pharm Sci; 2019 Mar; 130():107-113. PubMed ID: 30633968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies.
    Daily EB; Aquilante CL
    Pharmacogenomics; 2009 Sep; 10(9):1489-510. PubMed ID: 19761371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies to further investigate the inhibition of human liver microsomal CYP2C8 by the acyl-β-glucuronide of gemfibrozil.
    Jenkins SM; Zvyaga T; Johnson SR; Hurley J; Wagner A; Burrell R; Turley W; Leet JE; Philip T; Rodrigues AD
    Drug Metab Dispos; 2011 Dec; 39(12):2421-30. PubMed ID: 21911547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical Differences between Enzyme Sources in Sensitivity to Detect Time-Dependent Inactivation of CYP2C8.
    Kahma H; Filppula AM; Launiainen T; Viinamäki J; Neuvonen M; Evangelista EA; Totah RA; Backman JT
    Drug Metab Dispos; 2019 Apr; 47(4):436-443. PubMed ID: 30709838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clarification of the Mechanism of Clopidogrel-Mediated Drug-Drug Interaction in a Clinical Cassette Small-dose Study and Its Prediction Based on In Vitro Information.
    Kim SJ; Yoshikado T; Ieiri I; Maeda K; Kimura M; Irie S; Kusuhara H; Sugiyama Y
    Drug Metab Dispos; 2016 Oct; 44(10):1622-32. PubMed ID: 27457785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.
    Nguyen L; Holland J; Miles D; Engel C; Benrimoh N; O'Reilly T; Lacy S
    J Clin Pharmacol; 2015 Sep; 55(9):1012-23. PubMed ID: 25854986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.